BiomX (PHGE) has a ROE of 684.26%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow684.26%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
BiomX (PHGE) currently reports a ROE of 684.26%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore BiomX's ROE history and peer comparisons.
BiomX's ROE of 684.26% is higher than the Healthcare sector average of 11.15%. That is roughly 6034.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but BiomX's current 684.26% should be judged against Healthcare norms (sector average: 11.15%) and against PHGE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 684.26%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for BiomX, and consider following PHGE for alerts when major investors trade the stock.
BiomX is classified in the Healthcare sector. On ROE, it currently shows 684.26% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHGE with unrelated industries.